Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

KRX-0401 Perifosine

Drug (Brand/Generic)

KRX-0401 (perifosine)

Company/Licensee

Keryx Biopharmaceuticals

Therapy Class

Oral inhibitor

Product Description

Anti-cancer agent that inhibits Akt

Current Indication

Extending time to progression and improving overall response of refractory multiple myeloma

Market Sector

Multiple myeloma

Development Status

Phase III for multiple myeloma and refractory advanced colorectal cancer
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM
Close
Close
Close

Go Top